TABLE 5.

Treatment-related adverse events in the intent-to-treat population of patients with complicated intra-abdominal infections receiving continuous or intermittent infusions of piperacillin-tazobactam

Adverse event	No. (%) of patients treated with:		P value
	Continuous infusion (n = 130)	Intermittent infusion (n = 132)
Gastrointestinal disorders	6 (4.6)	4 (3.0)	0.583
Diarrhea	5 (3.8)	3 (2.3)	0.499
Infections and infestations	7 (5.4)	4 (3.0)	0.375
Metabolism or nutritional disorders	1 (0.8)	5 (3.8)	0.213
Hypokalemia	1 (0.8)	4 (3.0)	0.370
Nervous system disorders	1 (0.8)	4 (3.0)	0.370